167 completed, 69 terminated, 23 unknown, 22 recruiting. 202 Phase 2, 85 Phase 1, 24 Phase 3, 22 Not applicable, 16 Phase 4.
Follow Alemtuzumab: new trials by email Literature Review of Alemtuzumab trials Research Report on Alemtuzumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus - Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum | Phase 2 | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2026-11-01 | 2026-09-24 |
| Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease Cyclophosphamide 50mg, Abatacept, Alemtuzumab - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 45 | 2026-09-01 | 2026-07-23 |
| Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia | Phase 1 / Phase 2 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 90 | 2026-07-08 | 2026-10-13 |
| Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study Base-edited hematopoietic stem and progenitor cells, Alemtuzumab, Sirolimus - CD40L-HyperIgM Syndrome | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 1 | 2025-07-16 | 2026-07-31 |
| 131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD) 131I-apamistmab, Sirolimus, Campath - Sickling Disorder Due to Hemoglobin S | Phase 1 | Recruiting | Columbia University | 24 | 2025-04-28 | 2026-06-10 |
| Allo HSCT for High Risk Hemoglobinopathies Alemtuzumab, Total Body Irradiation, Cell Infusion - Graft Failure, Sickle Cell Disease | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 62 | 2024-11-19 | 2026-06-04 |
| Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells - Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2024-04-17 | 2026-08-13 |
| Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody Daratumumab, Alemtuzumab, Sirolimus - Sickle Cell Disease | Phase 2 | Recruiting | Children's National Research Institute | 12 | 2024-04-03 | 2025-09-26 |
| Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation Alemtuzumab - Allogeneic Hematopoietic Cell Transplantation | Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 60 | 2023-01-11 | 2026-06-12 |
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma UCART20x22, CLLS52 - B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1 / Phase 2 | Recruiting | Cellectis S.A. | 80 | 2022-11-01 | 2025-08-24 |
| Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD? Alemtuzumab Injection [Campath] - Sickle Cell Disease | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 20 | 2022-07-15 | 2023-06-22 | |
| TMLI and Alemtuzumab for Treatment of Sickle Cell Disease Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy - Sickle Cell Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 20 | 2022-07-13 | 2026-07-30 |
| ADAs to Alemtuzumab Alemtuzumab - Multiple Sclerosis | Completed | Queen Mary University of London | 15 | 2022-07-12 | 2026-03-02 | |
| Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists Sirolimus, Cyclophosphamide, Alemtuzumab - Chronic Granulomatous Disease | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 50 | 2022-07-08 | 2026-10-13 |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection - Lymphoma, Non-Hodgkin, Lymphoma, T-Cell | Phase 1 | Unknown | Lanzhou Institute of Biological Products Co., Ltd | 71 | 2021-12-20 | 2022-09-28 |
| A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis | Active not recruiting | Biogen | 1178 | 2021-09-24 | 2026-10-15 | |
| Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial Autologous Hematopoietic Stem Cell Transplantation, Ocrelizumab, Alemtuzumab - Relapsing-Remitting Multiple Sclerosis | Phase 2 | Terminated | Universitätsklinikum Hamburg-Eppendorf | 1 | 2021-08-27 | 2022-03-16 |
| Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Busulfan test dose, Fludarabine, Busulfan - Lymphoproliferative Disorders, Autoimmune Lymphoproliferative | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2020-09-22 | 2026-10-19 |
| Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT) - Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis | Phase 3 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 156 | 2020-08-17 | 2026-10-20 |
Showing 20 of 309. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (58) · Leukemia (52) · Lymphoma (37) · Anemia, Sickle Cell (34) · Myelodysplastic Syndromes (28) · Multiple Sclerosis (23) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Hodgkin Disease (22) · Lymphoma, Non-Hodgkin (22) · Anemia, Aplastic (19) · Leukemia, Myeloid, Acute (18) · Multiple Myeloma (17) · Graft vs Host Disease (15) · Recurrence (15) · Myeloproliferative Disorders (14)
Baylor College of Medicine (18) · Genzyme, a Sanofi Company (17) · M.D. Anderson Cancer Center (17) · Masonic Cancer Center, University of Minnesota (14) · National Heart, Lung, and Blood Institute (NHLBI) (12) · National Cancer Institute (NCI) (11) · National Institute of Allergy and Infectious Diseases (NIAID) (11) · Northwestern University (9) · Dana-Farber Cancer Institute (6) · German CLL Study Group (6) · Mayo Clinic (6) · University of Wisconsin, Madison (6) · Columbia University (5) · Fred Hutchinson Cancer Center (5) · Paul Szabolcs (5)
United States (223) · United Kingdom (20) · Canada (19) · Germany (19) · France (14) · Austria (12) · Italy (12) · Sweden (11) · Poland (8) · Denmark (7) · Netherlands (7) · Russia (7) · Spain (7) · Belgium (6) · Czechia (6)
Paul Orchard, MD (5) · Clive S. Zent, MD (4) · Elizabeth M Kang, M.D. (4) · Paul Szabolcs, MD (4) · Andrew Artz, MD (3) · Andrew M Yeager, MD (3) · George Carrum, MD (3) · Issa F. Khouri, MD (3) · John F Tisdale, M.D. (3) · Malcolm K Brenner, MD (3) · Richard Burt, MD (3) · Robert Krance, MD (3) · A.M. James Shapiro, MD, PhD (2)
PMID 36240296, PMID 34882037, PMID 42133908, PMID 30144037, PMID 31654272, PMID 31675266, PMID 31762387, PMID 32539719, PMID 32710396, PMID 33414927, PMID 34035833, PMID 36619856, PMID 37272540, PMID 37745914, PMID 39935588, PMID 21586746, PMID 22067384, PMID 23438305, PMID 23547837, PMID 24477186, PMID 27590291, PMID 27658437, PMID 28835401, PMID 29674506, PMID 31144568, PMID 34378446, PMID 34724566, PMID 40010689, PMID 41871072, PMID 11986207, PMID 12543862, PMID 16123718, PMID 17018123, PMID 18339140, PMID 18418404, PMID 18510632, PMID 18550258, PMID 18584865, PMID 18759253, PMID 18946064, PMID 19454532, PMID 19597025, PMID 19643983, PMID 19863336, PMID 19900571, PMID 20007560, PMID 20383216, PMID 20595516, PMID 20659956, PMID 20841509
2005 (4), P30CA015704 (4), U10CA031946 (4), 2008 (2), 2009 (2), 2014 (2), P01CA018029 (2), P30CA015083 (2), UM1AI109565 (2), 2004 (1), 2016 (1), 2017 (1), P30CA014236 (1), P30CA033572 (1), P30CA043703 (1)